How does naltrexone compare to disulfiram (Antabuse) for the treatment of alcohol use disorder in terms of efficacy, safety, contraindications, and appropriate patient selection?

Naltrexone vs Disulfiram for Alcohol Use Disorder

Naltrexone is preferred over disulfiram (Antabuse) for most patients with alcohol use disorder, particularly when liver disease is present or suspected, due to superior safety profile and evidence-based efficacy in reducing relapse. However, disulfiram may be superior in highly supervised settings with strong family support and when complete abstinence is the goal.

Key Clinical Decision Points

When to Choose Naltrexone

Naltrexone should be your first-line choice for:

• Patients with any degree of alcohol-associated liver disease (ALD) 1
• Patients seeking to reduce drinking or maintain abstinence with less intensive supervision
• Those who cannot guarantee supervised medication administration
• Patients with hepatotoxicity concerns from other medications

The 2020 AASLD guidelines explicitly state that disulfiram is not recommended for use in patients with ALD 1, while naltrexone is FDA-approved and recommended (though with hepatotoxicity monitoring) 2. Naltrexone works as an opioid receptor antagonist that reduces alcohol craving and the rewarding effects of drinking 3.

Dosing: 50 mg daily orally or 380 mg monthly intramuscular injection 1

When to Choose Disulfiram

Disulfiram may be superior when:

• Patient has guaranteed daily supervised administration by family member or healthcare provider
• Complete abstinence (not reduction) is the treatment goal
• Patient has NO liver disease or hepatic impairment
• Patient is highly motivated for aversive therapy 4

The evidence shows disulfiram outperforms naltrexone in supervised settings: one pragmatic trial found 86% remained abstinent with disulfiram versus 44% with naltrexone when family supervision was ensured 5. Another multicenter trial showed disulfiram superior in reducing heavy drinking days and increasing abstinent days during continuous supervised medication 6.

Critical caveat: Disulfiram's efficacy completely depends on open-label use with supervision. Blinded studies show no efficacy because the deterrent effect requires patient awareness 7.

Safety and Contraindications

Naltrexone Concerns

• Hepatotoxicity: Can cause hepatocellular injury; monitor liver function 2
• Not studied specifically in ALD patients but considered safer than disulfiram 1
• Contraindicated in acute hepatitis or hepatic failure per FDA label 3
• Must be opioid-free for 7-10 days before starting to avoid precipitated withdrawal 3

Disulfiram Concerns

• Contraindicated in hepatic insufficiency per multiple guidelines 4
• Poor tolerability with higher side effect rates 2, 8
• Can cause coagulopathy and serious drug interactions 8
• Risk of severe reactions if alcohol consumed (flushing, nausea, arrhythmia, dyspnea) 9
• Little evidence it enhances abstinence without supervision 2

Comparative Efficacy Data

The evidence reveals a nuanced picture:

• Supervised settings: Disulfiram superior - mean time to relapse 119 days vs 63 days with naltrexone 5; more abstinent days in supervised trials 6
• Unsupervised/typical clinical practice: Naltrexone preferred - Cochrane review confirms naltrexone lowers relapse risk 2
• Craving reduction: Naltrexone significantly reduces craving more than disulfiram 5
• Treatment persistence: Extended-release naltrexone shows better persistence than oral formulations 10

A 2014 meta-analysis found disulfiram efficacious only in open-label studies with supervision (Hedges' g = 0.70); blinded studies showed no benefit 7. This fundamentally limits disulfiram's real-world applicability.

Practical Treatment Algorithm

Step 1: Assess for liver disease

• If ANY liver disease present → Choose naltrexone (or acamprosate/baclofen as alternatives) 1, 4
• If no liver disease → Proceed to Step 2

Step 2: Evaluate supervision availability

• If daily supervised administration guaranteed by family/provider → Consider disulfiram for complete abstinence goal 5, 6
• If supervision unreliable → Choose naltrexone 2

Step 3: Define treatment goal

• Harm reduction/drinking reduction → Naltrexone (or nalmefene) 11
• Complete abstinence maintenance → Naltrexone or acamprosate first-line; disulfiram second-line only if supervised 11

Step 4: Monitor and adjust

• Naltrexone: Check liver enzymes at baseline and periodically 1
• Disulfiram: Requires open-label use; patient must understand consequences of drinking 7
• Both: Combine with counseling/psychosocial support for optimal outcomes 2, 12

Common Pitfalls to Avoid

1. Using disulfiram in patients with any liver disease - explicitly contraindicated 4, 1
2. Prescribing disulfiram without ensuring supervision - renders it ineffective 7
3. Using blinded disulfiram trials to guide practice - these show no efficacy 7
4. Starting naltrexone without adequate opioid-free period - risks precipitated withdrawal 3
5. Expecting medication alone to work - both require psychosocial support 2, 13
6. Ignoring patient preference and motivation - critical for adherence 4, 11

Bottom Line

For the majority of patients with AUD, naltrexone is the safer and more practical choice, particularly given the high prevalence of undiagnosed liver disease in this population 1. Disulfiram remains a viable option only in the specific context of guaranteed supervision and absence of liver disease, where it may actually outperform naltrexone for maintaining complete abstinence 5, 6. The 2020 AASLD guidelines make clear that both naltrexone and acamprosate may be considered with counseling to decrease relapse 2, but disulfiram's role is increasingly limited due to safety concerns and requirement for supervised administration.